Diabetes prevalence will increase in Europe up to 13% - Farmaprojects

news

24/11/2022

Diabetes prevalence will increase in Europe up to 13%

According to the International Diabetes Federation (IDF) Atlas, diabetes prevalence (9.2%) and number of people with diabetes (61 million) in EUR Region will increase 13 % by 2045. EUR Region has the highest number of children and adolescents with type 1 diabetes (295,000) as well as the highest incidence annually with 31,000 new cases per year.

The EUR Region has also the second highest average cost per person with diabetes (USD 3,086). In 2021, 189.3 billion USD was spent on diabetes, representing 19.6% of the total spent worldwide.

These figures clearly reflect the importance of diabetes treatment in European health systems and the need to ensure sustainability in patient care.

In the sense, generic drugs play a fundamental role in the treatment of patients. According to Medicines for Europe, almost 20 million people across Europe are now being treated for diabetes with generics (around 30%). However, the expected increase in the prevalence of this disease announced by the IDF may generate a significant problem for public health systems, which will have to face a considerable rise in the number of patients.

© 2022, Farmaprojects. All Rights Reserved.

For more information and updates regarding available dossiers and dossiers under development please contact Sales Department.
DISCLAIMER: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

© 2022, Farmaprojects. All Rights Reserved.

For more information and updates regarding available dossiers and dossiers under development please contact Sales Department.
DISCLAIMER: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.